Das ovarielle Überstimulationssyndrom (OHSS)

Zusammenfassung Das ovarielle Überstimulationssyndrom (OHSS) ist ein Krankheitsbild, das in seltenen Fällen im Rahmen einer künstlichen Befruchtung nach Ovulationsinduktion mit humanem Choriongonadotropin (hCG) auftreten kann. Die genaue Pathophysiologie, die zum OHSS führt, ist nach wie vor nicht vollständig geklärt. Vermutet wird eine erhöhte vaskuläre Permeabilität im Bereich der Ovarien und deren umgebender Gefäße. Das zur Ovulationsinduktion verabreichte hCG spielt eine herausragende Rolle, da es die Aktivierung des ovariellen Renin-Angiotensin-Systems induziert. Besonders gefährdet sind junge und schlanke Frauen mit hyperandrogenämischen Zyklusstörungen und polyzystischem Ovarialsyndrom (PCOS). Pathophysiologie, Präventionsmaßnahmen und Behandlungsstrategie werden im Folgenden diskutiert. Abstract Ovarian hyperstimulation syndrome (OHSS) is a relatively rare complication that occurs during in vitro fertilization (IVF) following ovulation induction with human chorionic gonadotropin (hCG). The exact pathophysiology that leads to OHSS is still not fully elucidated. It is presumably due to increased vascular permeability in the area of the ovaries and their surrounding vessels. The hCG administered to induce ovulation likely plays a pivotal role, as it activates the ovarian renin–angiotensin system. Young and slim women with hyperandrogenism and polycystic ovary syndrome (PCOS) are particularly at risk. Pathophysiology, preventive measures, and treatment strategies are discussed in the article. Similar content being viewed by others Literatur Tsampras N, Palinska-Rudzka K, Alebrahim Y, Craciunas L, Mathur R (2025) Prevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline. Hum Fertil 28(1):2441827. https://doi.org/10.1080/14647273.2024.2441827 Dietrich K, Ludwig M, Griesinger G (Hrsg) (2020) Reproduktionsmedizin, 2. Aufl. Springer, Berlin Gullo G, Cucinella G, Stojanovic V et al (2024) Ovarian hyperstimulation syndrome (OHSS): A narrative review and legal implications. J Pers Med 14(9):915. https://doi.org/10.3390/jpm14090915 Wallach EE, Navot D, Bergh PA, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261 Nastri CO, Ferriani RA, Rocha IA et al (2010) Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 27:121–128 Bergh PA, Navot D (1992) Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 9(5):429–438. https://doi.org/10.1007/BF01204048 Wallach EE, Morris RS, Paulson RJ (1994) Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril 62(6):1105–1114 Dahan MH, Fatemi HM, Polyzos NP, Garcia-Velasco JA (2024) Pathogenesis and management in OHSS. In: Handbook of Current and Novel Protocols for the Treatment of Infertility. Academic Press, S 197–209 Kosaka K, Fujiwara H, Yoshioka S, Fujii S (2007) Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22(6):1647–1651 Golan A, Ron-El R, Herman A, Soffer Y (1989) Ovarian hyperstimulation syndrome: an updated review. Obstet Gynecol Surv 44:430–440 Aboulghar MA, Mansour RT (2003) Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 9:275–289 Olivennes F (2010) Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin Reprod Med 28:463–467 Andersen AN, Nelson SM, Fauser BCJM et al (2017) Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 107(2):387–396 Ishihara, Osamu, and Joan-Carles Arce. “Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.” Reproductive biomedicine online 42.5 (2021): 909-918. Griesinger G, Schultz L, Bauer T et al (2011) Ovarian hyperstimulation syndrome prevention by GnRH agonist triggering of final oocyte maturation in a GnRH antagonist protocol with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 95(6):2029–2033 Jiang L, Qiu Y, Xu L, Chang R, He F (2024) Effect of aromatase inhibitors for preventing ovarian hyperstimulation syndrome in infertile patients undergoing IVF: a systematic review and meta-analysis. Reprod Biol Endocrinol 22(1):85 Siristatidis CS, Papapanou M, Maheshwari A, Vaidakis D (2025) In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 2: Humaidan P, Quartarolo J, Papanikolaou EG (2010) Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 94(2):389–400 Wang TH, Horng SG, Chang CL et al (2002) hCG-induced ovarian hyperstimulation syndrome is associated with up-regulation of VEGF. J Clin Endocrinol Metab 87(7):3300–3308 Kolibianakis EM, Papanikolaou EG, Tournaye H et al (2007) Triggering final oocyte maturation using different doses of hCG: a randomized pilot study in PCOS patients. Fertil Steril 88(5):1382–1388 Griesinger G, Diedrich K, Devroey P, Kolibianakis EM (2006) GnRH agonist for triggering final oocyte maturation in GnRH antagonist protocols: a systematic review and meta-analysis. Hum Reprod Update 12(2):159–171 Nardo LG, Cheema P, Gelbaya TA et al (2006) Optimal length of ‘coasting’ in IVF cycles at risk of OHSS. Hum Fertil 9(3):175–180 Zeng C, Shang J, Jin AM et al (2019) The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study. Arch Gynecol Obstet 300(1):223–233. https://doi.org/10.1007/s00404-019-05163-3 Salama KM, Ragab AHM, El Sherbiny MF et al (2017) Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study. BMC Womens Health 17:1–9 Soares SR (2012) Etiology of OHSS and use of dopamine agonists. Fertil Steril 97(3):517–522 Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ (2021) Dopamine agonists for preventing OHSS. Cochrane Database Syst Rev 4: Alvarez C, Alonso-Muriel I, García G et al (2007) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22(12):3210–3214 Rubenfeld ES, Dahan MH (2021) Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome? Obstet Gynecol Sci 64(4):345–352 Palomba S, Costanzi F, Nelson SM, Caserta D, Humaidan P (2023) Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol 21(1):67 Shahhosseini R et al (2025) The Early Versus Standard Administration of Cabergoline to Prevent Ovarian Hyperstimulation Syndrome in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Randomized Clinical Trial. Int J Women’s Health Reproduction Sci 2:13 Author information Authors and Affiliations Corresponding author Ethics declarations Interessenkonflikt Z. Kristof gibt an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Additional information Hinweis des Verlags Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral. QR-Code scannen & Beitrag online lesen Rights and permissions About this article Cite this article Kristof, Z. Das ovarielle Überstimulationssyndrom (OHSS). Gynäkol. Prax. 35, 87–92 (2025). https://doi.org/10.1007/s41974-025-00375-9 Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s41974-025-00375-9